Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6355685 | 0.92 | PDE4A (0.41) | GAAMAPTADORA2ANPSR1 | |
| SCHEMBL6355684 | 0.92 | PDE4A (0.41) | GAAMAPTADORA2ANPSR1 | |
| SCHEMBL28310651 | 0.85 | PDE4A (0.47) | ADORA2A | |
| SCHEMBL16027743 | 0.82 | ADORA2A (0.49) | MAPTADORA2AADORA2B | |
| SCHEMBL27604724 | 0.82 | PDE4A (0.39) | ADORA2A | |
| SCHEMBL27604723 | 0.82 | PDE4A (0.39) | ADORA2A | |
| SCHEMBL18834194 | 0.81 | HSD17B10 (0.49) | ADORA2B | |
| SCHEMBL4707209 | 0.79 | GAA (0.40) | GAAADORA2AADORA2B | |
| SCHEMBL4707211 | 0.79 | GAA (0.40) | GAAADORA2AADORA2B | |
| SCHEMBL18833826 | 0.78 | ADORA2A (0.46) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305910-A1 | Substituted Xanthines and Methods of Use Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
| EP-2970303-B9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-2970303-B1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305910-A1 | Substituted Xanthines and Methods of Use Thereof | TRPC5, TRPC7, TRPC4 | GAA 2882/4885MAPT 2951/4885ADORA2A 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.